KOSDAQBiotech & Pharma185490

EyeGene

₩1,715▲ 0.35%2026-11-18 close
Market Cap
₩74.1B
Turnover
₩77,543,559
Volume
50K
Shares out.
43.2M
PER
—
PBR
1.5×
EPS
-₩527
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

EyeGene: Recombinant Toxin Approval Test Amid Ongoing Losses

EyeGene filed for export approval of its recombinant botulinum toxin in August 2026, but most of its revenue still comes from wholesale of its largest shareholder's products and losses have continued for five straight quarters, so the pace of commercialization after approval is the key item to watch.

  1. 1

    Revenue structure: as of year-end 2025, 99.7% of revenue came from wholesale of products of the largest shareholder, BMI Korea, according to a Green Economy report, with no own-manufactured product sales and no own new-drug approvals.

  2. 2

    Annual results: the operating loss narrowed from KRW 24.1 billion in 2022 to KRW 9.85 billion in 2025, but the company has posted losses for four consecutive years from 2022 to 2025. The controlling-shareholder net loss widened to KRW 15.7 billion in 2025.

  3. 3

    Quarterly results: the controlling-shareholder net loss for the last four quarters (Q4 2025 to Q3 2026) totals KRW 18.3 billion. Q3 2026 revenue was KRW 1.17 billion, up 6.1% year on year, while the operating loss was KRW 2.51 billion.

  4. 4

    Pipeline timeline: the company expects the recombinant toxin export approval within 2026 and targets entry into domestic clinical procedures in the first half of 2027, while the meningococcal vaccine trial is slated for completion by 2027.

  5. 5

    Governance: the largest shareholder holds 23.18%, and a Green Economy report said KRW 7.04 billion in loans to an Australian subsidiary were treated as unrecoverable losses. Related-party transactions are an issue to re-check in the annual report notes.

02

Business structure

EyeGene describes itself as a bio venture whose main business is R&D in medicine and pharmacy, but its revenue structure looks closer to wholesale.

According to a Green Economy report, 99.7% of revenue as of year-end 2025 came from wholesale of products of its largest shareholder, BMI Korea, with no own-manufactured product sales and no own new-drug approvals in 25 years.

BMI Korea became the largest shareholder after investing KRW 15.0 billion in December 2023 and raised its stake from 21.48% to 23.18% through a rights offering. The pipeline has four strands.

The first is the recombinant botulinum toxin EG-rBTX100, for which BMI Korea applied to the Ministry of Food and Drug Safety for export approval on August 12, 2026.

The second is non-exclusive out-licensing of the toxin manufacturing technology, which the company plans to pursue with global firms in the United States, Europe and China. The third is the tetravalent meningococcal vaccine EG-MCV4, which received domestic Phase 2/3 approval.

The fourth is the mRNA vaccine BMI2012, which received Phase 1 IND approval on August 12, 2026. In recombinant toxins, a Chinese developer, Claruvis Biotech, received FDA IND clearance for its liquid recombinant toxin YY003 in September 2024, so competition already exists.

In September 2026, EyeGene was selected as a co-research institution in two Korean ARPA-H-style projects under the Ministry of Health and Welfare, with total government funding of KRW 26.0 billion over five years.

Because each pipeline's monetization depends on approval and clinical timelines, near-term revenue contribution is limited.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1B-₩1.6B−150.1%
2025Q4₩800M-₩3.3B−420.4%
2026Q1₩1.3B-₩3.5B−277.7%
2026Q2₩1.3B-₩3.9B−294.8%
2026Q3₩1.2B-₩2.5B−215.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5.3B-₩24.1B-₩26.5B−455.1%−39.7%16.6%
2023₩3.1B-₩27.1B-₩22.4B−866.6%−35.5%21.4%
2024₩3.4B-₩13.3B-₩12.1B−395.0%−24.1%28.5%
2025₩3.6B-₩9.9B-₩15.7B−276.2%−27.5%25.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue fell from KRW 5.29 billion in 2022 to KRW 3.13 billion in 2023, a 41.0% decline year on year, and then rose to KRW 3.36 billion in 2024 (up 7.4%) and KRW 3.57 billion in 2025 (up 6.3%), so revenue has grown for two consecutive years from 2024 to 2025. 2022 was the largest year and 2023 the smallest among 2022 to 2025.

The operating loss widened from KRW 24.1 billion in 2022 to KRW 27.1 billion in 2023, then narrowed to KRW 13.3 billion in 2024 and KRW 9.85 billion in 2025. The operating margin moved from -455.1% in 2022 to -866.6% in 2023, -395.0% in 2024 and -276.2% in 2025, so the loss relative to revenue has eased since 2023.

The controlling-shareholder net loss was KRW 26.5 billion in 2022, KRW 22.4 billion in 2023 and KRW 12.1 billion in 2024, then widened to KRW 15.7 billion in 2025.

The net loss including non-controlling interests was KRW 19.1 billion in 2025, and the gap from the controlling-shareholder figure reflects non-controlling interests. The debt ratio rose from 16.6% in 2022 to 28.5% in 2024 and eased to 25.4% in 2025, and total equity at year-end 2025 was KRW 54.3 billion.

Operating cash outflow narrowed from KRW 18.6 billion in 2022 and KRW 20.1 billion in 2023 to KRW 12.2 billion in 2024 and KRW 5.98 billion in 2025.

On a quarterly basis, revenue fell 29.5% quarter on quarter to KRW 774 million in Q4 2025, rose to KRW 1.27 billion in Q1 2026 and KRW 1.34 billion in Q2 2026, and then declined 13.0% to KRW 1.17 billion in Q3 2026.

The operating loss widened from KRW 1.65 billion in Q3 2025 and KRW 3.25 billion in Q4 2025 to KRW 3.53 billion in Q1 2026 and KRW 3.95 billion in Q2 2026, before narrowing to KRW 2.51 billion in Q3 2026.

The controlling-shareholder net loss of KRW 8.83 billion in Q4 2025 was far larger than that quarter's operating loss of KRW 3.25 billion, and the reason for that gap should be checked in the notes to the annual report.

05

Industry analysis

EyeGene's business spans three markets. In vaccines, Korea's government plans to spend a mRNA vaccine development support program of KRW 500 billion through 2028 to secure vaccine sovereignty, which creates policy demand for domestic mRNA developers; EyeGene's consortium BMI2012 is at Phase 1.

In the same mRNA field, GC Biopharma has entered Phase 2 with its own lipid nanoparticle platform, so domestic competition is clear. Overseas, Moderna and Merck reported Phase 3 success for a personalized mRNA melanoma vaccine, which supports the clinical relevance of the technology.

In botulinum toxin, the company itself estimates the global market at about KRW 9 trillion, growing roughly 10% a year toward KRW 25 trillion within ten years; this is the company's own projection.

In recombinant toxins, Claruvis Biotech of China has received FDA IND clearance for its liquid product and is an early competitor.

EyeGene stresses that its recombinant design avoids the strain-origin controversy of wild-type cultivation, but whether this differentiation converts into market share depends on clinical and export results.

Most pipelines are still at non-clinical or clinical stages, so individual approval timelines matter more to earnings than the industry cycle.

06

Outlook

The schedules confirmed by the company and press reports are as follows. For the recombinant toxin EG-rBTX100, the two companies expect export approval within 2026, and after approval BMI Korea plans exports mainly to Asia from 2027.

EyeGene plans to complete non-clinical work, file a domestic clinical trial application after export approval, and enter domestic clinical procedures in the first half of 2027.

The company is pursuing non-exclusive out-licensing of its toxin manufacturing technology, which could create a new revenue stream if contracts are signed, but the size and timing of any deal have not been disclosed.

In vaccines, the goal for the tetravalent meningococcal vaccine EG-MCV4 is to complete Phase 2 and Phase 3 trials in sequence by 2027 and then seek product approval.

The mRNA COVID-19 candidate BMI2012 is supported by a government program, targeting Phase 1 completion and Phase 2 IND approval between December 2025 and March 2027, with product approval targeted for 2028.

On funding, a rights offering at the end of 2025 raised KRW 22.6 billion, earmarked for toxin development, the meningococcal vaccine, an AAV macular degeneration therapy and the mRNA vaccine.

In August 2026, research on an AAV macular degeneration therapy designed to reduce injection burden was published in an international journal. CEO Choi Seok-geun said in a July 2026 interview that the company aims to become a profitable bio company that can stand on its own within three years. Whether this vision is realized can be gauged by whether export revenue is actually recorded.

07

Valuation

PER
—
PBR
1.5×
ROE
-40.0%
EPS
-₩527
BPS
₩1,106
Dividend per share
₩0

The multiples read differently depending on the earnings structure. Because the controlling-shareholder net loss has continued over the last four quarters, the price-to-earnings ratio is not calculated.

The price-to-book ratio sits above book value, meaning the shares trade at a premium to net assets, and that premium rests more on future approval and export timelines than on past earnings. The dividend yield is below the industry average and shareholder returns are effectively negligible.

A Green Economy report noted that accumulated deficit at the end of March 2026 was KRW 180.9 billion, 8.4 times paid-in capital. Compared directly with profitable listed bio companies, EyeGene's stage and revenue structure differ, so the same multiple yardstick is hard to apply. Valuation therefore depends more on pipeline timing and funding than on current earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Export filing and Asian export plans

The recombinant botulinum toxin EG-rBTX100 was filed for export approval on August 12, 2026. The two companies expect approval within 2026, and if granted, BMI Korea plans exports mainly to Asia from 2027.

Actual approval would be the first step toward adding manufacturing-based revenue to a structure that is currently wholesale-driven.

External funding from government projects

In September 2026, EyeGene was selected as a co-research institution in two Korean ARPA-H-style projects, with government funding of KRW 26.0 billion in total over five years. A KDCA-supported mRNA Phase 1 program also provides about KRW 656.7 million in research funding. These sources can help carry the vaccine pipeline without relying solely on the company's own capital.

Licensing option on toxin manufacturing technology

The company is pursuing non-exclusive out-licensing of its recombinant botulinum toxin manufacturing technology to global pharma and biotech firms in the United States, Europe and China. The company says finished toxin can be produced at a biosafety level 2 facility.

If contracts are signed, this structure could generate licensing income without the company having to build its own sales channel.

09

Bear factors

Revenue depends mostly on the largest shareholder's wholesale

According to a Green Economy report, 99.7% of revenue as of year-end 2025 came from wholesale of products of the largest shareholder, BMI Korea. The company has no own-manufactured product sales and no own new-drug approvals.

When a related party accounts for this much of sales, earnings depend heavily on the terms of those transactions and the largest shareholder's business direction.

Persistent losses and accumulated deficit

The company posted operating losses for four consecutive years from 2022 to 2025, and the controlling-shareholder net loss over the last four quarters totals KRW 18.3 billion. The Q3 2026 operating loss was KRW 2.51 billion.

A Green Economy report put consolidated accumulated deficit at KRW 180.9 billion at the end of March 2026. Some quarters show narrower losses, but the earnings base for a move into profit has not yet appeared in reported results.

Subsidiary loans and reported capital impairment

A Green Economy report said cumulative loans of KRW 7.04 billion to EyeGene Australia, a wholly owned Australian subsidiary, were treated by the company as unrecoverable losses. The same report said the subsidiary had negative net assets at the end of Q1 2026.

The report also raised as a governance issue that the CEO holds directorships at BMI Korea and at this subsidiary.

10

Risk factors

Clinical and approval timeline risk

If the toxin export approval is not granted within 2026, the 2027 export and domestic clinical entry schedules could slip together. The meningococcal vaccine targets completion of Phase 2/3 trials by 2027, and the mRNA vaccine targets product approval in 2028. Any delay would extend the period of loss-making operations.

Related-party and governance risk

Most sales come from wholesale of products of the largest shareholder, BMI Korea, and a Green Economy report said loans to an Australian subsidiary were treated as unrecoverable. The CEO's concurrent directorships were also raised as an issue.

The terms of these transactions and the substance of the subsidiary should be checked in the related-party notes of the annual report.

Financing and balance sheet risk

The company raised KRW 22.6 billion through a rights offering at the end of 2025, but as losses continue, further fundraising remains possible. A Green Economy report said total equity fell from KRW 54.2 billion at year-end 2025 to KRW 50.9 billion at the end of March 2026. The size and method of future financing could also affect the shareholding structure.

11

What to watch next

  1. By year-end 2026

    Whether export approval is granted for the recombinant botulinum toxin EG-rBTX100. Approval would make the 2027 Asian export schedule more concrete, while a delay would push back the timing of export revenue.

  2. By March 31, 2027

    Filing of the 2026 annual report. It is the next regular filing and will show the full-year results, the notes explaining the gap between the Q4 2025 controlling-shareholder net loss and operating loss, the treatment of subsidiary loans, and related-party transaction details.

  3. First half of 2027

    Whether the domestic clinical trial application for EG-rBTX100 is filed and domestic clinical procedures begin. The start of BMI Korea's Asian exports is also a checkpoint in the same period.

  4. March 2027

    The target for completing the Phase 1 trial of the KDCA-supported mRNA COVID-19 vaccine BMI2012 and for approval of the Phase 2 IND. Whether this target is met will indicate the pace of the vaccine pipeline.

  5. During 2027

    The target for completing Phase 2 and Phase 3 trials of the tetravalent meningococcal vaccine EG-MCV4. Whether a product approval application follows will determine when vaccine sales could first begin.

12

Overall view

EyeGene's disclosed results show operating and controlling-shareholder net losses for four consecutive years from 2022 to 2025, with the operating loss narrowing from KRW 24.1 billion in 2022 to KRW 9.85 billion in 2025.

The controlling-shareholder net loss over the last four quarters totals KRW 18.3 billion, and as of year-end 2025, 99.7% of revenue came from wholesale of the largest shareholder's products.

The business centers on a pipeline running from export approval of the recombinant botulinum toxin to clinical work on the tetravalent meningococcal vaccine and Phase 1 of the mRNA vaccine.

Whether these schedules convert into sales will determine any turning point in results, and the export approval outcome in late 2026 and the 2026 annual report in 2027 are the first points to check.

Government research projects and the option to license toxin manufacturing technology could provide external funding and new revenue. On the other side, related-party transaction structure, the treatment of subsidiary loans, the accumulated deficit and the possibility of further fundraising remain financial risks.

Because the last four quarters show net losses, the share price multiples cannot be explained on an earnings basis, and the price reflects a premium to book value tied to future timelines.

This report does not present an investment opinion, rating or target price, and it summarizes facts confirmed through filings and press reports.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. eyegene.co.kr
  2. eyegene.co.kr
  3. pharmnews.com
  4. etoday.co.kr
  5. etoday.co.kr
  6. biospectator.com
  7. greened.kr
  8. supple.kr
  9. biospectator.com
  10. vegannews.co.kr
  11. digitaltoday.co.kr
  12. m.thinkpool.com
  13. greened.kr
  14. hansbiz.co.kr
  15. digitaltoday.co.kr
  16. tradingkey.com
  17. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis